Dendrite ramification affects synaptic strength and plays a crucial role in memory. Previous studies revealed a correlation between beta 2-adrenergic receptor dysfunction and Alzheimer's disease (AD), although the mechanism involved is still poorly understood. The current study investigated the potential effect of the selective β 2 -adrenergic receptor antagonist, ICI 118551 (ICI), on Aβ deposits and AD-related cognitive impairment. Morris water maze test results demonstrated that the performance of AD-transgenic (TG) mice treated with ICI (AD-TG/ICI) was significantly poorer compared with NaCl-treated AD-TG mice (AD-TG/NaCl), suggesting that β 2 -adrenergic receptor blockage by ICI might reduce the learning and memory abilities of mice. Golgi staining and immunohistochemical staining revealed that blockage of the β 2 -adrenergic receptor by ICI treatment decreased the number of dendritic branches, and ICI treatment in AD-TG mice decreased the expression of hippocampal synaptophysin and synapsin 1. Western blot assay results showed that the blockage of β 2 -adrenergic receptor increased amyloid-β accumulation by downregulating hippocampal α-secretase activity and increasing the phosphorylation of amyloid precursor protein. These findings suggest that blocking the β 2 -adrenergic receptor inhibits dendrite ramification of hippocampal neurons in a mouse model of AD.
Introduction
Alzheimer's disease (AD) is a common form of dementia that typically occurs during old age (Schott et al., 2006; Doody et al., 2014; Dubois et al., 2014; Nelson et al., 2014; Aron and Yankner, 2016; Canter et al., 2016; Reiman, 2016; Roy et al., 2016; Shrestha and Klann, 2016; Tycko, 2016) . The disease is characterized by a progressive degenerative change in brain regions that leads to serious damage to cognitive functions, including memory, decision-making, language and orientation (Li et al., 2013) . Amyloid beta (Aβ) deposits in brain regions are universally present among AD patients and are considered the fundamental cause of the disease (Tanzi, 2005; Gao et al., 2016) . However, currently there is no effective cure for this devastating disease (Choi et al., 2016; The Lancet, 2016) .
Early symptoms of AD include difficulty in remembering recent events, and as short-term memory loss progresses, patients begin to have problems with languages, disorientation, change of mood, along with other behavior problems that affect personal and social life (Artero et al., 2003; Cummings et al., 2016; Fray et al., 2016; Kida et al., 2016; Lauterbach, 2016; Makovac et al., 2016; Nagata et al., 2016) . HistologiBlocking of β 2 -AR in a mouse model of AD Activated β 2 -AR provides a new direction for AD treatment Exacerbated cognitive deficits
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Increased Aβ by downregulating hippocampal α-secretase expression and increasing the phosphorylation of amyloid precursor protein cally, disease usually presents with two major characteristics: neurofibrillary tangles and amyloid plaques. The plaques are composed of Aβ, a peptide cleaved from the amyloid precursor protein (APP) (Querfurth and LaFerla, 2010) . The neurofibrillary tangle is formed by hyperphosphorylation of a microtubule-associated protein, tau (Ballatore et al., 2007; Kim et al., 2015; Koliatsos and Xu, 2015) . Clinical manifestations suggest that tau and Aβ accumulation play an essential role in the pathology of the disease. However, these histological changes are only observed when AD patients have succumbed to the disease (Querfurth and LaFerla, 2010) .
In recent years, a number of studies have demonstrated a link between AD and β 2 -adrenergic receptor (β 2 -AR) functions (Ni et al., 2006; Yu et al., 2008) . For example, an epidemiological study reported a correlation between low AD risk and the use of non-selective β-ARs antagonists among people with high blood pressure (Khachaturian et al., 2006) . A genetic study also found a correlation between β 2 -AR gene polymorphisms and the high incidence of late-onset AD (Li et al., 2013) . Interestingly, an animal study showed that chronic β 2 -AR agonist treatment resulted in greater numbers of Aβ deposits among mice contained a mixed background of C57Bl/6 and 129 and when the β 2 -AR was blocked, Aβ induced by acute stress was significantly decreased (Li et al., 2013) . In addition, β 2 -AR is well known for its involvement in memory and normal learning. Studies have shown that the activation of β 2 -AR promotes the long-term potentiation of synapses. Indeed, studies demonstrated a modulatory effect of β 2 -AR in memory building and consolidation. β 2 -AR activation also alleviates the negative effects of amyloid-β on long-term potentiation (Li et al., 2013) . All this evidence suggests a relationship between β 2 -AR and AD. However, the role of β 2 -AR and the mechanism underlying the correlation of β 2 -AR and AD in AD pathogenesis are still largely unknown.
In this study, an AD mouse model was used to investigate the potential effect of a selective β 2 -AR antagonist on Aβ deposits and the AD-related cognitive impairment. The mechanism underlying the relationship between β 2 -AR and AD was also investigated.
Materials and Methods
Animals
Twenty 6-month old female amyloid precursor protein/presenilin 1 double transgenic (APPswe/PS1dE9) mice (AD-TG) (weight 22-27 g) and 20 female wild type (non-TG) mice (weight 22-27 g) were purchased from Jackson Laboratory (Bar Harbor, ME, USA).
The animal study was approved by the Committee of the Ethics of Animal Experiments of Yancheng Vocational Institute of Health Sciences, China. The experimental procedure followed the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1986) .
APPswe/PS1dE9 transgenic mice have been widely used as a model of AD (Lin et al., 2016) . Mice were raised in accordance with a standard protocol, with a 12-hour light/dark cycle (light on from 7:00 a.m. and light off from 7:00 p.m), at 23 ± 1°C and 52 ± 5% humidity with free access to tap water and rodent diet for 5 days prior to experimental interventions and behavioral tests.
Drug treatment
AD-TG (n = 16) and wild type control (non-TG) mice (n = 16) were sub-grouped as follows: non-TG/NaCl and AD-TG/ NaCl saline control groups (n = 8 per group) receiving injections of 0.9% NaCl (1 mg/kg per day, intraperitoneally) for 2 months; and non-TG/ICI and AD-TG/ICI groups receiving β 2 -AR antagonist treatment, ICI 118551 (Sigma-Aldrich, St Louis, MO, USA) (1 mg/kg per day, intraperitoneally) for 2 months (n = 8 per group). ICI 118551 was all dissolved in saline (0.9% NaCl) before use.
Morris water maze test
To evaluate the memory and spatial learning of all animals, the Morris water maze test was performed in the morning as described in a previous study (Zhang et al., 2012) . After AD-TG and non-TG mice were subjected to saline or ICI 118551 for 2 months, the Morris water maze test was performed. A computerized tracking system (DigBeh-MM; Shanghai Jiliang Software Technology Co., Ltd., Shanghai, China) was utilized to monitor the trajectory of all mice. During the test, for the training trials, a hidden platform with a diameter of 5 cm was maintained in the same quadrant, 1.5 cm below the surface of water.
In every trial, all mice had up to 1 minute to locate the hidden platform and escape onto it. If a mouse did not locate the hidden platform within 1 minute, the experimenter would manually guide the mouse to the platform and keep it there for 10 seconds. The trial was carried out four times daily for 6 days. The escape latency refers to the time that a mouse spent in finding the platform, and this formed the spatial learning score.
Following the last training trial, the probe trial was carried out to test the spatial memory by allowing all animals to swim freely for 1 minute in the maze with the platform removed. After finding the platform, the mice were allowed to stay on it for 20 seconds and were then placed in their home cage for 30 seconds until the start of the next acquisition trial. If a mouse did not find the platform within 90 seconds, it was guided onto the platform and allowed to remain on it for 20 seconds. After training, the mice were placed back in their home cage until retention testing 24 hours later. A 60-second probe trial was performed 5 minutes after the injection of propofol or saline. During the probe test, the platform was not present, and the times crossing the platform and the time spent in the target quadrant (3 rd quadrant) was recorded. The escape latency before reaching the hidden platform location, the swimming distance in the 3 rd quadrant and counts of crossing the 3 rd quadrant within 1 minute during the probe trial were recorded.
Golgi staining and immunohistochemistry
After AD-TG and non-TG mice were subjected to saline or ICI 118551 for 2 months, brain tissues were harvested. For Golgi staining, half of the brain was fixed with 400 mL Golgi fixative (0.9% NaCl, 5% formaldehyde, 5% potassium dichromate, and 5% chloral hydrate) in the dark. The brain was removed and used for Golgi staining as previously described (Li et al., 2013) . In brief, the brain was post-fixed for 3 days in the same Golgi fixative, and impregnated with 1.0% aqueous silver nitrate solution for 3 days. Coronal brain sections of hippocampal tissue were cut at 35 μm. The images were observed by microscopy (Olympus, Tokyo, Japan).
For immunohistochemistry staining, the brains were subjected to 4% formaldehyde in PBS for 2 days and bathed in PBS with sodium azide (0.02%). The fixed brains were then sliced into 50-µm thick sections. The sections were rinsed with Tris buffered saline (TBS), and incubated with 3% H 2 O 2 for 30 minutes, then subjected to a 15-minute incubation of TBS-A and a 30-minute incubation of TBS-B. The sections were then probed with specific primary antibody rabbit monoclonal anti-Aβ (1:200; Abcam, Cambridge, MA, USA) at 4°C overnight. Sections were rinsed with TBS before a 2-hour incubation of goat anti-rabbit secondary antibody at room temperature. Finally, the reaction product was visualized with diaminobenzidine in 0.1 M phosphate-buffered saline for 30 seconds. Immunohistochemical staining results were observed under a light microscope (Olympus), and quantitative assessment of relative changes in immunohistochemical staining was performed by Image Pro Plus 6.0 software (Media Cybernetics, Atlanta, GA, USA). The average number of dendritic branches of pyramidal neurons in the hippocampus was analyzed by Golgi staining.
Enzyme linked immunosorbent assay
Amyloid beta 40 (Aβ 40 ) and amyloid beta 42 (Aβ 42 ) enzyme linked immunosorbent assay plates were purchased from Invitrogen (Waltham, MA, USA) and experiments were conducted according to the manufacturer's instructions.
Western blot assay
Proteins (20 μg) from each sample of hippocampus were loaded on a 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel. After electrophoresis, the proteins were transblotted to a polyvinylidene difluoride membrane (Millipore) blocked with 5% non-fat milk solution with Tris buffered saline Tween (TBST) for 60 minutes. The protein blots were then incubated with the following specific primary antibodies: rabbit monoclonal anti-Synapsin-1 (1:500), rabbit polyclonal anti-synaptophysin (1:1,000), rabbit anti-monoclonal 6E10 (1:500), rabbit polyclonal anti-PS1(1:1,000), rabbit monoclonal anti-APP (1:1,000) (all from Abcam, Cambridge, MA, USA); rabbit polyclonal anti-p-APP, rabbit monoclonal anti-secreted amyloid precursor protein-α (sAPPα) and rabbit monoclonal anti-secreted amyloid precursor protein-β (sAPPβ), and rabbit monoclonal anti-β-actin (all from Cell Signaling, Beverly, MA, USA) at 4°C overnight. The membranes were then washed with TBST and subjected to a 2-hour incubation with the following secondary antibody: donkey anti-rabbit IgG (H&L) antibody (1:5,000; Rockland Immunochemicals, Inc., Pottstown, PA, USA) at room temperature for 2 hours. Finally, the protein blots were visualized using the ECL Plus Western Blotting Substrate (TIANGEN, Beijing, China). Optical density values were analyzed with PDQuest 7.2.0 software (Bio-Rad, Richmond, CA, USA). β-Actin was used as an internal reference.
Statistical analysis
Continuous variables are expressed as the mean ± SD. All statistical analyses were performed using SPSS 19.0 software (IBM, Armonk, NY, USA). Significant differences between groups were assessed by one-way analysis of variance followed by the least significant difference test. A two-sided significant value of P < 0.05 was considered statistically significant.
Results
Blocking β 2 -AR exacerbated memory deficits in AD-TG mice To determine the effect of blocking β 2 -AR on spatial memory in AD-TG mice, the Morris water maze test was conducted. A previous study demonstrated that AD-TG mice showed Aβ accumulation, synaptic deficits and memory impairments at 8 months (Li et al., 2013) . Therefore, AD-TG mice were injected with an β 2 -AR antagonist (ICI 118551) at 8 months of age and their learning and memory behaviors were assessed at 10 months of age (Chai et al., 2017) . For the Morris water maze training, mice received 4 rounds of training each day, for 5 days until the probe trial. The latency for finding the hidden platform was significantly increased in AD-TG mice compared with the wild type control (non-TG) mice (P < 0.01) ( Figure 1A) . The performances of AD-TG mice treated with ICI (AD-TG/ICI) in the Morris water maze were significantly poorer at 3 and 4 days, compared with NaCl-treated AD-TG mice (AD-TG/NaCl) ( Figure 1A) (P < 0.01). In addition, AD-TG/ICI mice had poorer Morris water maze performance at 4 and 5 days, compared with the non-TG group. However, ICI had no significant impact on the learning and memory behavior of non-TG mice ( Figure  1A ; P < 0.01).
To evaluate the spatial memory of mice, probe trials were performed after 5 days of training trial. The reference memory of AD-TG/ICI mice was significantly poorer (with significantly longer latency before reaching the location of the platform), compared with the other groups ( Figure 1B ; P < 0.01). In addition, the AD-TG/ICI group had a slower swim speed in the probe test compared with the AD-TG group ( Figure  1C) . Moreover, fewer counts of location crossing during the trial were reported for AD-TG/ICI mice compared with untreated AD-TG mice ( Figure 1D ; P < 0.01). These findings suggest that ICI has a significant negative effect on the cognitive function of AD-TG mice.
Blocking β 2 -AR inhibited dendrite ramification in the mouse hippocampus Synaptic plasticity is essential for learning and memory and (A) Probe trials were performed after 5 days of training. Representative Golgi stained hippocampal pyramidal neurons in groups of wild type control (non-TG/Nacl), amyloid precursor protein/presenilin 1 double transgenic (AD-TG/NaCl), and AD-TG/NaCl mice given ICI 118551 (AD-TG/ ICI) under light microscopy. The dendritic branches (indicated by arrows) were decreased in AD-TG/NaCl mice compared with non-TG mice. Blocking β 2 -AR with ICI treatment further decreased the number of dendritic branches. Scale bars: 100 μm. (B) The number of dendritic branches was quantified from randomly selected neurons. The average counts of dendritic branches were significantly decreased in AD-TG/NaCl mice compared with non-TG/NaCl mice, and blocking β 2 -AR with ICI treatment further decreased the number of dendritic branches. *P < 0.05, **P < 0.01, vs. non-TG/NaCl. Data are expressed as the mean ± SD (n = 8, one-way analysis of variance followed by the least significant difference test). Wild type control (non-TG) and AD-TG mice were sub-grouped: saline control group, injections of 0.9% NaCl, termed non-TG/NaCl and AD-TG/ NaCl; β 2 -AR antagonist treatment group, mice were administered ICI 118551 (1 mg/kg per day, intraperitoneally), termed AD-TG/ICI. rd quadrant (C) and counts of crossing the 3 rd quadrant within 1 minute during the probe trial (D). Data are expressed as the mean ± SD (n = 8, one-way analysis of variance followed by the least significant difference test). *P < 0.05, **P < 0.01, vs. non-TG/NaCl group. Wild type control (non-TG) and AD-TG mice were sub-grouped: saline control group, injections of 0.9% NaCl, termed non-TG/NaCl and AD-TG/NaCl; β 2 -AR antagonist treatment, mice were administered ICI 118551 (1 mg/kg per day, intraperitoneally), termed AD-TG/ICI. can be evaluated by the observation of dendrite morphology (Li et al., 2013) . To investigate the mechanisms involved in exacerbated memory deficits in AD-TG mice by blocking β 2 -AR, the average number of dendritic branches of pyramidal neurons in the hippocampus was analyzed by Golgi staining. The average counts of dendritic branches were significantly decreased in AD-TG mice compared with non-TG mice (Figure 2A and B; P < 0.01). Noticeably, the blocking of β 2 -AR with ICI treatment further decreased the number of dendritic branches (Figure 2A and B; P < 0.05).
To further explore the molecular mechanisms underlying β 2 -AR blocking exacerbated memory deficits, the expression of several synaptic proteins was examined by western blot assay. Results showed that ICI treatment in AD-TG mice further decreased the expression of synaptophysin and synapsin 1 (P < 0.01, P < 0.05; Figure 3A and B).
Blocking of β 2 -AR increased Aβ accumulation in AD-TG mice
The mice were treated with ICI at 8 months of age and the alteration of Aβ was measured at 10 months of age. Results showed that 2 months of ICI treatment on AD-TG mouse could increase Aβ accumulation in hippocampus (Figure 4A and B; P < 0.01). The blocking of β 2 -AR with ICI increased (A) Protein samples of hippocampus were harvested after 5 days of training. The protein levels of synaptophysin and synapsin I in the hippocampus of wild type control (non-TG/NaCl), amyloid precursor protein/presenilin 1 double transgenic (AD-TG/NaCl), and AD-TG/NaCl mice given ICI 118551 (AD-TG/ICI) were determined by western blot assay. (B) Synaptophysin and synapsin I signal intensity was quantified by ImageJ software and normalized by β-actin expression. *P < 0.05, **P < 0.01, vs. non-TG/NaCl. Data are expressed as the mean ± SD (n = 8, one-way analysis of variance followed by the least significant difference test). Wild type control (non-TG) and AD-TG mice were sub-grouped: saline control group, injections of 0.9% NaCl, termed non-TG/NaCl and AD-TG/NaCl; β 2 -AR antagonist treatment group, mice were administered ICI 118551 (1 mg/kg per day, intraperitoneally), termed non-TG/ICI and AD-TG/ICI. Experiments were conducted in triplicate. The levels of amyloid beta 40 (Aβ 40 ) and amyloid beta 42 (Aβ 42 ) in hippocampi were detected by enzyme linked immunosorbent assay. *P < 0.05, **P < 0.01, vs. non-TG/NaCl. Data are expressed as the mean ± SD (n = 8, one-way analysis of variance followed by the least significant difference test). Wild type control (non-TG) and AD-TG mice were sub-grouped: saline control group, injections of 0.9% NaCl, termed non-TG/NaCl and AD-TG/ NaCl; β 2 -AR antagonist treatment group, mice were administered ICI 118551 (1 mg/kg per day, intraperitoneally), termed AD-TG/ICI.
Aβ 40-42 production (Figure 4C and D; P < 0.01, P < 0.05).
To explore the mechanisms underlying the upregulation of Aβ production by ICI, the expression of PS1, APP and p-APP was evaluated by western blot assay. A significant increase of APP phosphorylation and PS1 was observed in AD-TG mice compared with non-TG control mice. Notably, ICI treatment further increased the protein expression of p-APP and PS1 (Figure 5A and B; P < 0.01). Furthermore, changes in the sAPPα, sAPPβ, and 6E10 ( Figure  5A and B) proteins were detected, which are involved in Aβ synthesis and degradation in AD-TG mice (Nussbaum and Ellis, 2003) . Compared with non-TG mice, the protein levels of sAPPα and sAPPβ were significantly decreased in AD-TG mice (P < 0.01). Blocking β2-AR significantly reduced sAPPα and sAPPβ levels compared with untreated AD-TG mice (P < 0.01).
Discussion
Because the global population age is increasing, it has been suggested that the prevalence of AD might be increased 4-fold by the middle of this century (Alzheimer's Association, 2013; Kunz et al., 2015; Wang et al., 2015) . Aging might also lead to many other conditions, such as cardiovascular diseases (Yang and Ming, 2012; Carvalho-de-Souza et al., 2013; Qi and Xie, 2013; Corella and Ordovas, 2014; Shah et al., 2014; Baralla et al., 2015; Chang et al., 2016; Harshman and Shea, 2016; Sahoo et al., 2016; Sallam and Laher, 2016; Silva-Palacios et al., 2016) . Because cardiovascular diseases such as hypertension are commonly comorbid with AD, it is important to clarify the effect of certain treatments on both conditions (Li et al., 2013) . In this study, we investigated β-blockers, and showed that blocking β2-AR by ICI in AD-TG mice substantially inhibited dendrite ramification in hippocampal neurons and downregulated the postsynaptic density proteins synapsin 1 and synaptophysin. Moreover, blocking β 2 -AR increased Aβ accumulation by downregulating α-secretase activity and increasing the phosphorylation of APP. Our findings suggest that β 2 -AR might be a novel target for AD treatment.
Postsynaptic dendritic spine remodeling plays a fundamental role in the formation of memory (Becker et al., 2017; Kulasiri et al., 2017; Schiff et al., 2017) . Morphological diversity represents functional properties of dendritic spine (Jiang et al., 2015) . Recently, Li and colleagues reported that the chronic oral administration of a β-adrenergic agonist mitigated Aβ-related hippocampal impairments in wild type mice (Li et al., 2013) . In the present study, blocking β 2 -AR decreased dendritic complexity and decreased spine density. This suggests that β 2 -AR antagonists might lead to memory impairment, consistent with the above evidence.
Morphological changes in dendrites are multifactorial, including the influence of neuronal activity (Whitford et al., 2002) , and cadherin and β-catenin (Abe et al., 2004) . A protective effect of non-selective β-ARs antagonists against AD was previously reported (Khachaturian et al., 2006) . Moreover, genetic studies of AD revealed that β 2 -AR gene polymorphisms are associated with the risk of late-onset AD (Insel, 2011) . Presynaptic neurotransmitter release involves many vesicle-related proteins such as synapsin I and synaptophysin. These proteins are biomarkers for synaptic plasticity of neural networks (Pieribone et al., 1995) . In this study, the role of β 2 -AR in AD was investigated. Blocking β 2 -AR exacerbated the decreased expression of synaptophysin and synapsin I. These data might be related to the functional and structural mechanisms underlying the β 2 -AR-mediated amelioration of memory deficits in AD-TG mice.
Environmental factors such as stress-activated receptors including β 2 -AR, are considered risk factors for AD (Fratiglioni et al., 2004) . Ni et al. (2006) reported that a β2-AR agonist stimulated γ-secretase activity and accelerated Aβ plaque formation in vivo and in vitro (Ni et al., 2006) . Their experiments mimicked abnormal β 2 -AR activation, which might result from a response to stress and might contribute to Aβ accumulation in the pathology of AD. Moreover, Aβ may induce β 2 -AR internalization and degradation, leading to the impairment of adrenergic and glutamatergic activities (Wang et al., 2011) . Indeed, a decrease in β 2 -AR levels was observed in different areas of AD brains, and the β 2 -AR response was also decreased in fibroblasts isolated from AD patients (Huang and Gibson, 1993) . Aβ is generated by the consecutive cleavage of APP by two proteases, i.e., β-secretase and γ-secretase (presenilin, PS1/PS2) (Nishitomi et al., 2006) . In our study, although the levels of Aβ 40 and Aβ 42 were increased in ICI-treated AD-TG mice, the total levels of APP and PS1 were not significantly changed compared with NaCl-treated AD-TG mice. Thus, alterations of APP in ICI-treated AD-TG mice were rare. These findings, along with other previous animal studies, indicated that chronic β 2 -AR agonist treatment might increase Aβ deposits in transgenic mice, while β-blocker treatment reduced stress-related acute Aβ production (Yu et al., 2010) . We also showed that blocking β 2 -AR with ICI significantly increased the phosphorylation of APP and increased Aβ production in AD-TG mice whilst downregulating α-secretase activity. These results might shed light on the mechanism underlying the (A) The protein levels of presenilin 1 (PS1), amyloid precursor protein (APP), phosphorylation of APP (p-APP), secreted amyloid precursor protein-α (sAPPα), secreted amyloid precursor protein-β (sAPPβ) and amyloid beta (6E10) in the hippocampus were measured by western blot assay. (B) Protein signal intensity was quantified by ImageJ software and normalized by β-actin expression. *P < 0.05, **P < 0.01, vs. non-TG/NaCl. Data are expressed as the mean ± SD (n = 8, one-way analysis of variance followed by the least significant difference test). Wild type control (non-TG) and AD-TG mice were sub-grouped: saline control group, injections of 0.9% NaCl, termed non-TG/NaCl and AD-TG/NaCl; β2-AR antagonist treatment group, mice were administered ICI 118551 (1 mg/kg per day, intraperitoneally), termed non-TG/ICI and AD-TG/ICI. Experiments were conducted in triplicate. correlation between β 2 -AR and AD. In summary, blocking β 2 -AR exacerbated cognitive deficits and decreased dendritic branches accompanied by the downregulation of synaptic protein levels. Furthermore, blocking β 2 -AR increased Aβ accumulation by downregulating α-secretase activity and increasing the phosphorylation of APP in AD-TG mice. These results suggest that targeting β 2 -AR pharmacologically might provide a new direction for AD treatment.
